Nirmatrelvir

Nirmatrelvir

API (a component of Paxlovid)

Summary

This publication is to provide technical information on M4ALL’s initial work on nirmatrelvir. The disclosed development opens up a path to three new complete routes, offering options for a scalable, chromatography-free process to synthesize nirmatrelvir from key starting materials. M4ALL replaced key cost-driving reagents HATU and Burgess Reagent with affordable DCC and trifluoroacetic anhydride. In addition, we developed an alternative API assembly strategy leveraging the action of T3P to remove one step from the overall process (work is ongoing to optimize this process). These improvements deliver the final API in higher yield and lower overall cost while maintaining quality requirements.

(Pre-print) Efforts to Develop a Cost -Effective and Scalable Synthetic Process for Nirmatrelvir